Prostate specific antigen determination kit and preparation method thereof

Through the use of PSA antibody-gold nanoparticle composite recognition probe, the existing fPSA detection methods are solved, and the simplified detection process and efficient prostate-specific antigen detection are realized, which is suitable for primary screening and large Batch inspection.

CN118937662AActive Publication Date: 2024-11-12DAAN GENE CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202310536362.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-12
Estimated Expiration
2043-05-12

AI Technical Summary

Technical Problem

The existing fPSA detection methods are costly and have poor repetition, which cannot meet the needs of grassroots screening.

Method used

Using PSA antibody-gold nanoparticle composite recognition probe, the sample processing and detection process is simplified through the surface plasmon resonance effect, and a prostate-specific antigen assay kit is provided, and blood sample processing and specific detection is achieved using reagents R1 and R2 to achieve Qualitative and quantitative analysis.

Benefits of technology

It reduces detection cost and technical complexity, shortens detection time, improves detection sensitivity and specificity, and is suitable for large-scale detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004226392360000091
    Figure BDA0004226392360000091
  • Figure BDA0004226392360000101
    Figure BDA0004226392360000101
  • Figure BDA0004226392360000102
    Figure BDA0004226392360000102
Patent Text Reader

Abstract

The invention belongs to the technical field of medical examination and determination, and relates to a prostate specific antigen determination kit and a preparation method thereof, the prostate specific antigen determination kit comprises a reagent R1 and a reagent R2; the reagent R1 comprises a first buffer solution, a surfactant, a first preservative and a first stabilizer; the reagent R2 comprises a PSA antibody-gold nanoparticle composite recognition probe, a first sealing agent, a second sealing agent, a second preservative, a second buffer solution and a second stabilizer. According to the technical scheme provided by the invention, the operation process can be simplified, the detection cost and the technical complexity are reduced, and the detection time is shortened.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of medical testing and determination, and more specifically, to a prostate specific antigen determination kit and a preparation method thereof. Background Art

[0002] Human prostate specific antigen (PSA) is a single-chain glycoprotein secreted by epithelial cells of the prostate acini and ducts. PSA is a serine protease that belongs to the class of kallikrein in function. It participates in the liquefaction process of semen and is an important indicator used in the diagnosis and differentiation of benign and malignant prostate diseases and the postoperative follow-up of prostate cancer patients.

[0003] One of the most common cancers that kills men worldwide is prostate cancer. Symptoms associated with prostate cancer usually appear in the late stages, when more aggressive treatment is needed. Therefore, it is imperative to develop devices that can detect it early, thereby hopefully preventing the spread of the disease and allowing patients to recover faster after treatment. According to recent reports, both the digital rectal exam (DRE) and the prostate-specific antigen (PSA) blood test are used to determine if a patient has prostate cancer, with the PSA test being more sensitive and a better predictor of prostate cancer.

[0004] fPSA (free prostate-specific antigen) has potential value in diagnosing prostate cancer. Commonly used detection methods for fPSA include chemiluminescent immunoassay, which has high sensitivity and strong specificity, but the instruments and reagents are expensive and cannot be used for primary screening; enzyme-labeled assay (EIA), which has the disadvantages of poor repeatability and high requirements for the quality of operators; and radioimmunoassay (RIA), which has environmental pollution problems. Summary of the invention

[0005] The technical problem to be solved by the embodiments of the present application is that the fPSA detection in the prior art has high cost and poor repeatability.

[0006] In order to solve the above technical problems, the present application provides a prostate specific antigen determination kit, which adopts the following technical solution:

[0007] Reagent R1 and reagent R2;

[0008] The reagent R1 includes a first buffer, a surfactant, a first preservative and a first stabilizer;

[0009] The reagent R2 includes a PSA antibody-gold nanoparticle composite recognition probe, a first blocking agent, a second blocking agent, a second preservative, a second buffer and a second stabilizer.

[0010] Further, the PSA antibody is a mouse monoclonal anti-PSA antibody, and the gold nanoparticles are cysteamine gold nanoparticles;

[0011] The gold nanoparticles have a particle size of 24-28 nm and a potential of 34-40 mV;

[0012] The concentration of the mouse monoclonal anti-PSA antibody was 0.2 mg / mL.

[0013] Further, the first buffer and the second buffer are independently selected from Tris buffer;

[0014] The surfactant is selected from Tween 20;

[0015] The first preservative and the second preservative are independently selected from NaN3;

[0016] The first stabilizer and the second stabilizer are independently selected from TritonX-100;

[0017] The first blocking agent is a tert-butyl carbamate solution prepared with tetrahydrofuran as solvent;

[0018] The second blocking agent is a complex comprising triethanolamine, glycine and casein.

[0019] Furthermore, the concentration of the Tris buffer is 100mmoL / L;

[0020] The concentration of Tween 20 is 5 g / L;

[0021] The concentration of NaN3 is 0.1% (w / v);

[0022] The concentration of TritonX-100 is 20 g / L;

[0023] The concentration of the tert-butyl carbamate solution is 1-3 mM;

[0024] The mass ratio of the triethanolamine, the glycine and the casein is 1.5:1:2.

[0025] Furthermore, the kit also includes calibrators and quality control products;

[0026] The calibrators include different concentrations of prostate-specific antigen;

[0027] The quality control products include prostate specific antigen at different concentrations.

[0028] Furthermore, the calibrant also includes a stabilizer or a preservative;

[0029] The stabilizer is selected from bovine serum albumin;

[0030] The preservative is selected from NaN3.

[0031] In order to solve the above technical problems, the present application also provides a method for preparing a prostate-specific antigen assay kit, which adopts the following technical solution:

[0032] Reagent R1 and reagent R2 are prepared and assembled to obtain a test kit;

[0033] Wherein, the reagent R1 comprises a first buffer, a surfactant, a first preservative and a first stabilizer;

[0034] The reagent R2 includes a PSA antibody-gold nanoparticle composite recognition probe, a first blocking agent, a second blocking agent, a second preservative, a second buffer and a second stabilizer.

[0035] Furthermore, the PSA antibody-gold nanoparticle composite recognition probe is prepared by the following steps:

[0036] Preparation of cysteamine gold nanoparticles;

[0037] The anti-PSA antibody is coated onto the cysteamine gold nanoparticles to prepare a PSA antibody-gold nanoparticle composite recognition probe.

[0038] Further, the cysteamine gold nanoparticles are prepared by the following steps:

[0039] Weigh mercaptoethylamine, chloroauric acid and sodium borohydride in parts by weight to prepare mercaptoethylamine solution, chloroauric acid solution and sodium borohydride solution respectively;

[0040] Mix the mercaptoethylamine solution and the chloroauric acid solution to obtain a mixed solution;

[0041] adding sodium borohydride solution into the mixed solution to carry out reduction reaction to obtain cysteamine gold nanoparticles; and / or

[0042] The step of coating the anti-PSA antibody onto the cysteamine gold nanoparticles to prepare the PSA antibody-gold nanoparticle composite recognition probe comprises:

[0043] adding the first blocking agent to the anti-PSA antibody to block the amino site to obtain a first blocking antibody;

[0044] Adding EDC and NHS to the first blocking antibody simultaneously to activate the carboxyl site, thereby obtaining an activated anti-PSA antibody;

[0045] The activated anti-PSA antibody and the cysteamine gold nanoparticles are subjected to a coupling reaction, and a second blocking agent is added to obtain a PSA antibody-gold nanoparticle composite solution;

[0046] Trifluoroacetic acid was added to the PSA antibody-gold nanoparticle composite solution, and the PSA antibody-gold nanoparticle composite recognition probe precipitate was obtained after centrifugation. The supernatant was removed and the solution was re-dissolved with Tris buffer.

[0047] Compared with the prior art, this application has the following beneficial effects:

[0048] The prostate-specific antigen assay kit provided by the present application utilizes the surface plasmon resonance effect of gold nanoparticles, performs simple treatment of blood samples through R1 reagent, reduces interference of other substances in the sample with the test results, and then specifically detects PSA through the anti-PSA antibody-gold nanoparticle composite recognition probe in R2 reagent. This kit can achieve preliminary qualitative analysis of the test sample by observing the change of its color with the naked eye, and can detect the content of prostate-specific antigen through the change of its absorbance value, thereby achieving quantitative purpose. The kit of the present application simplifies the operation process, reduces the detection cost and technical complexity, and shortens the detection time. DETAILED DESCRIPTION

[0049] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs; the terms used in the specification of the application herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" and any variations thereof in the specification and claims of this application are intended to cover non-exclusive inclusions. The terms "first", "second", etc. in the specification and claims of this application are used to distinguish different objects, not to describe a specific order.

[0050] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0051] In order to enable those skilled in the art to better understand the solution of the present application, the technical solution in the embodiments of the present application is clearly and completely described below.

[0052] An embodiment of the present application provides a prostate-specific antigen assay kit, which includes reagent R1 and reagent R2; reagent R1 includes a first buffer, a surfactant, a first preservative and a first stabilizer; reagent R2 includes a PSA antibody-gold nanoparticle composite recognition probe, a first blocking agent, a second blocking agent, a second preservative, a second buffer and a second stabilizer.

[0053] The kit of the present application is a dual-reagent detection kit. The blood sample is simply processed by reagent R1 to reduce the interference of other substances in the sample on the test results. Then, PSA is specifically detected by the anti-PSA antibody-gold nanoparticle composite recognition probe (Anti-PSA Antibody@CS-AuNPs) in reagent R2. The composite recognition probe will aggregate in large quantities to cause the solution to change color. The more obvious the change in its absorbance at the ultraviolet-visible absorption wavelength, the more obvious the change in its absorbance value. The content of prostate-specific antigen can be detected by the change in its absorbance value, thereby achieving the purpose of quantification.

[0054] In some embodiments, the PSA antibody is a mouse monoclonal anti-PSA antibody, the gold nanoparticles are cysteamine gold nanoparticles; the gold nanoparticles have a particle size of 24-28 nm and a potential of 34-40 mV; and the concentration of the mouse monoclonal anti-PSA antibody is 0.2 mg / mL.

[0055] Among them, cysteamine gold nanoparticles (CS-AuNPs) exhibit a bright wine red color.

[0056] In this embodiment, the gold nanoparticles are cysteamined to better bind to the PSA antibody. The gold nanoparticles have different properties due to their different particle sizes. The gold nanoparticles of 24-28 nm have a larger specific surface area and can better bind to the PSA antibody. The potential can change the receptor binding property on the surface of the gold nanoparticles. The potential is 34-40 mV, which can better achieve binding with antibodies and subsequent antigen-antibody reactions.

[0057] In some embodiments, the first buffer and the second buffer are independently selected from Tris buffer; the surfactant is selected from Tween 20; the first preservative and the second preservative are independently selected from NaN3; the first stabilizer and the second stabilizer are independently selected from TritonX-100; the first blocking agent is a tert-butyl carbamate solution prepared with tetrahydrofuran as solvent; and the second blocking agent is a complex comprising triethanolamine, glycine and casein.

[0058] In some embodiments, the concentration of Tris buffer is 100mmoL / L; the concentration of Tween 20 is 5g / L; the concentration of NaN3 is 0.1% (w / v); and / or, the concentration of TritonX-100 is 20g / L; the concentration of tert-butyl carbamate solution is 1-3mM / L; the mass ratio of triethanolamine, glycine and casein in the complex is 1.5:1:2.

[0059] Wherein, Tris buffer is conventional and commercially available. In some embodiments, the kit also includes calibrators and quality control products.

[0060] Calibrators are mainly used to calibrate measurement systems, evaluate measurement procedures, or assign values ​​to samples to be tested. Calibrators include different concentrations of prostate-specific antigen (fPSA).

[0061] Specifically, the calibrator and the quality control product contain fPSA of known concentration. For example, the calibrator contains 6 different concentrations of fPSA, namely 0 ng / ml, 0.5 ng / ml, 1 ng / ml, 2 ng / ml, 5 ng / ml and 10 ng / ml; the quality control product contains 2 different concentrations of fPSA, namely 2 ng / ml and 6 ng / ml.

[0062] In some embodiments, the calibrator and the quality control product further include a stabilizer or a preservative, wherein the stabilizer is selected from bovine serum albumin (BSA); and the preservative is selected from NaN3.

[0063] In some embodiments, the calibrator can be prepared in liquid form, dry powder, or lyophilized powder form.

[0064] In some embodiments, the controls include varying concentrations of prostate specific antigen.

[0065] Based on the above-mentioned prostate-specific antigen assay kit, the corresponding detection principle is:

[0066] Utilizing the SPR (Surface Plasmon Resonance) characteristics of gold nanoparticles, the absorbance value of gold nanoparticles at a specific wavelength will change with their dispersion state. For example, stably dispersed cysteamine-modified gold nanoparticles will have a large absorbance peak at 526nm. As the gold nanoparticles aggregate, their absorbance value at 526nm will decrease. The greater the aggregation, the greater the decrease in absorbance. A PSA antibody-gold nanoparticle composite recognition probe is formed by coating the surface of gold nanoparticles with anti-PSA antibodies. When fPSA is present in the sample to be tested, the composite recognition probe will specifically bind to it to cause the gold nanoparticles to aggregate, and the fPSA content can be detected by the decrease in its absorbance value at 526nm.

[0067] The prostate-specific antigen assay kit of the present application is used to quickly detect the content of prostate-specific antigen in human serum, mainly using the surface plasmon resonance effect of gold nanoparticles. This detection method can achieve preliminary qualitative analysis of the test sample by observing the change of its color with the naked eye, and at the same time, the content of prostate-specific antigen can be detected by the change of its absorbance value, thereby achieving quantitative purpose. This detection method has low detection cost and fast detection speed, and can meet large-scale detection work.

[0068] Based on the above-mentioned prostate-specific antigen assay kit, the present application also provides a method for preparing the prostate-specific antigen assay kit, comprising the following steps:

[0069] Reagent R1 and reagent R2 are prepared and assembled to obtain a test kit.

[0070] In some embodiments, the PSA antibody-gold nanoparticle composite recognition probe in reagent R2 is prepared by the following steps:

[0071] Preparation of cysteamine gold nanoparticles;

[0072] The anti-PSA antibody was coated onto cysteamine gold nanoparticles to prepare a PSA antibody-gold nanoparticle composite recognition probe.

[0073] Wherein, the cysteamine gold nanoparticles are prepared by the following steps:

[0074] Weigh mercaptoethylamine, chloroauric acid and sodium borohydride in parts by weight to prepare mercaptoethylamine solution, chloroauric acid solution and sodium borohydride solution respectively;

[0075] Mix the mercaptoethylamine solution and the chloroauric acid solution to obtain a mixed solution;

[0076] Sodium borohydride solution is added into the mixed solution to carry out reduction reaction, thereby obtaining cysteamine gold nanoparticles.

[0077] For example, the preparation method of cysteamine gold nanoparticles is as follows:

[0078] 1) Weigh 6-8 parts of mercaptoethylamine, 20-22 parts of chloroauric acid, and 2-4 parts of sodium borohydride by weight;

[0079] 2) The substance in step 1) is prepared into a solution and placed in a refrigerator at 4°C for later use;

[0080] 3) mixing the mercaptoethylamine solution and the chloroauric acid solution, and uniformly stirring the mixture under magnetic stirring at room temperature in a dark environment to obtain a mixture;

[0081] 4) adding the prepared sodium borohydride solution to the mixture and continuing stirring, so that the sodium borohydride reduces the chloroauric acid to stabilize the formed gold particles, and finally forms a clear and transparent wine red solution, which is the cysteamine gold nanoparticles;

[0082] 5) Filter the newly prepared cysteamine gold nanoparticles with a 0.22 μm filter membrane and store in a 4° C. refrigerator away from light for later use.

[0083] In some embodiments, the step of coating the anti-PSA antibody onto the cysteamine gold nanoparticles to prepare the PSA antibody-gold nanoparticle composite recognition probe comprises:

[0084] adding a first blocking agent to the anti-PSA antibody to block the amino site to obtain a first blocking antibody;

[0085] Adding EDC (1-ethyl-(3-dimethylaminopropyl) carbodiimide) and NHS (sodium salt of N-hydroxysulfosuccinimide) to the first blocking antibody simultaneously activates the carboxyl site to obtain an activated anti-PSA antibody;

[0086] The activated anti-PSA antibody and the cysteamine-modified gold nanoparticles are subjected to a coupling reaction, and a second blocking agent is added to obtain a PSA antibody-gold nanoparticle composite solution;

[0087] Trifluoroacetic acid was added to the PSA antibody-gold nanoparticle composite solution, and the PSA antibody-gold nanoparticle composite recognition probe precipitate was obtained after centrifugation. The supernatant was removed and the solution was re-dissolved with Tris buffer.

[0088] For example, the preparation method of the PSA antibody-gold nanoparticle composite recognition probe is as follows:

[0089] 1) preparing a tert-butyl carbamate (BOC) solution (first blocking agent) using tetrahydrofuran (THF) as a solvent; wherein the concentration of the tert-butyl carbamate solution is 1 to 3 mM;

[0090] 2) adding tert-butyl carbamate solution to the anti-PSA antibody at a volume ratio of 1:100 to block the amino sites;

[0091] 3) adding EDC and NHS to the above anti-PSA antibody at a volume ratio of 1:1:100 to activate the carboxyl site; wherein the concentration of EDC is 2-4 mM, and the concentration of NHS is 2-4 mM;

[0092] 4) The activated anti-PSA antibody and cysteamine-modified gold nanoparticles were mixed at a ratio of 1:300 for coupling, reacted at 37°C for 1 h, and a complex of triethanolamine, glycine, and casein (second blocking agent) was added to block the remaining carboxyl sites;

[0093] 5) Finally, trifluoroacetic acid was added to remove tert-butyl carbamate, and the mixture was centrifuged at 1,0000 rpm for 20 min to obtain a PSA antibody-gold nanoparticle composite recognition probe precipitate. The supernatant was removed and the mixture was re-dissolved with Tris buffer.

[0094] In some embodiments, calibrators and quality controls are prepared, and reagent R1, reagent R2, calibrators and quality controls are assembled into a kit.

[0095] Based on the above-mentioned prostate-specific antigen assay kit, the present application also provides a detection method of the prostate-specific antigen assay kit, comprising the following steps:

[0096] Step 1: Reagent preparation

[0097] Reagent R1 and reagent R2 of this kit are both liquid reagents and can be used directly. It is recommended to mix by inversion.

[0098] Step 2: Test conditions

[0099] The optimum temperature for the reaction of this kit with samples is 37°C, and the detection wavelength is 526nm.

[0100] Step 3: Calibration Procedure

[0101] First, use the calibrator provided with this kit to create a calibration curve, that is, perform the calibration operation, with the concentration of the calibrator as the horizontal axis and the corresponding △OD 526 The vertical axis is used, and nonlinear fitting, such as Spline, is used to draw the standard curve.

[0102] Step 4: Quality Control Procedures

[0103] To ensure the reliability of the test results, the quality control material provided with this kit is tested when testing each batch of samples. If the quality control fails, please follow the steps below to find the cause:

[0104] Check whether the parameter settings and light source are correct;

[0105] Check whether the cuvette and sample needle are clean;

[0106] Check water for contamination, bacterial growth can lead to incorrect results;

[0107] Check whether the reaction temperature meets the standard;

[0108] Check the expiration date of the test kit.

[0109] Step 5: Sample testing

[0110] Among them, the sample is a serum sample.

[0111] As shown in Table 1, the amounts and order of addition of R1, R2 reagents and samples are shown.

[0112] Table 1

[0113]

[0114] Step 6: Calculation of test results

[0115] A calibration curve was drawn with the concentration of the calibrator versus the corresponding ΔA, and the concentration of prostate-specific antigen in the sample was read from the calibration curve through the ΔA of the sample.

[0116] The following is a more specific description of the content of the present application in conjunction with specific embodiments, and further elaboration of the present application, but these embodiments are by no means limiting the present application.

[0117] Example 1

[0118] This embodiment is a prostate specific antigen assay kit, the components, packaging and quantity, as shown in Table 2.

[0119] Table 2

[0120]

[0121] Example 2

[0122] This example is an experiment on the linear range and minimum detection limit of samples of the prostate specific antigen assay kit.

[0123] 1. Linearity experiment

[0124] A high-concentration fPSA sample was diluted in multiples using a method known to those skilled in the art. The concentration after dilution was then measured using the kit prepared in the present application, and the average value was obtained by three measurements, and compared with the theoretical concentration to calculate the linear deviation.

[0125] It can be seen from Table 3 that the linear range of the kit of the present application can reach 1.0-12.0 ng / ml.

[0126] Table 3 Linear test results

[0127]

[0128]

[0129] 2. Minimum detection limit

[0130] By using a method known to those skilled in the art, the blank solution and several low-concentration samples diluted with physiological saline were measured 15 times, and the absorbance change was read. Then, the absorbance value of each sample after deducting the blank absorbance was calculated, and the mean and standard deviation were calculated.

[0131] The minimum detection limit is calculated using a 99.7% probability. The mean of each sample is subtracted by 3 times the respective standard deviation, and then compared with 3 times the standard deviation of the blank solution. If the former is higher than the latter, it is determined that there is a 99.7% probability that the minimum absorbance is greater than the blank absorbance, and the results can be reported quantitatively. The measurement results are shown in Table 4.

[0132] It can be seen from Table 4 that when the sample concentration is 1.0 ng / ml, the result after subtracting 3 times the standard deviation from the mean is higher than that of normal saline plus 3 times the standard deviation, and at this time the CV% is close to 20%, so the minimum detection limit of the detection reagent of the present application is 1.0 ng / ml.

[0133] Table 4 Detection limit experimental results

[0134]

[0135]

[0136] Obviously, the embodiments described above are only a part of the embodiments of the present application, rather than all the embodiments, but do not limit the patent scope of the present application. The present application can be implemented in many different forms. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present application more thorough and comprehensive. Although the present application is described in detail with reference to the aforementioned embodiments, for those skilled in the art, it is still possible to modify the technical solutions recorded in the aforementioned specific implementation methods, or to perform equivalent replacement of some of the technical features therein. All equivalent structures made using the specification of this application, directly or indirectly used in other related technical fields, are similarly within the scope of patent protection of this application.

Claims

1. A prostate specific antigen assay kit, characterized in that: include: Reagent R1 and reagent R2; The reagent R1 includes a first buffer, a surfactant, a first preservative and a first stabilizer; The reagent R2 includes a PSA antibody-gold nanoparticle composite recognition probe, a first blocking agent, a second blocking agent, a second preservative, a second buffer and a second stabilizer.

2. The prostate specific antigen assay kit according to claim 1, characterized in that: The PSA antibody is a mouse monoclonal anti-PSA antibody, and the gold nanoparticles are cysteamine gold nanoparticles; The gold nanoparticles have a particle size of 24-28 nm and a potential of 34-40 mV; The concentration of the mouse monoclonal anti-PSA antibody was 0.2 mg / mL.

3. The prostate specific antigen assay kit according to claim 1, characterized in that: The first buffer and the second buffer are independently selected from Tris buffer; The surfactant is selected from Tween 20; The first preservative and the second preservative are independently selected from NaN3; The first stabilizer and the second stabilizer are independently selected from TritonX-100; The first blocking agent is a tert-butyl carbamate solution prepared with tetrahydrofuran as solvent; The second blocking agent is a complex comprising triethanolamine, glycine and casein.

4. The prostate specific antigen assay kit according to claim 3, characterized in that: The concentration of the Tris buffer is 100mmoL / L; The concentration of Tween 20 is 5 g / L; The concentration of NaN3 is 0.1% (w / v); The concentration of TritonX-100 is 20 g / L; The concentration of the tert-butyl carbamate solution is 1-3 mM / L; The mass ratio of the triethanolamine, the glycine and the casein is 1.5:1:

2.

5. The prostate specific antigen assay kit according to claim 3, characterized in that: The kit also includes calibrators and quality control products; The calibrators include different concentrations of prostate-specific antigen; The quality control products include prostate specific antigen at different concentrations.

6. The prostate specific antigen assay kit according to claim 5, characterized in that: The calibrator also includes a stabilizer or a preservative; The stabilizer is selected from bovine serum albumin; The preservative is selected from NaN3.

7. A method for preparing a prostate-specific antigen assay kit, characterized in that: The following steps are involved: Reagent R1 and reagent R2 are prepared and assembled to obtain a test kit; Wherein, the reagent R1 comprises a first buffer, a surfactant, a first preservative and a first stabilizer; The reagent R2 includes a PSA antibody-gold nanoparticle composite recognition probe, a first blocking agent, a second blocking agent, a second preservative, a second buffer and a second stabilizer.

8. The method for preparing the prostate specific antigen assay kit according to claim 7, characterized in that: The PSA antibody-gold nanoparticle composite recognition probe is prepared by the following steps: Preparation of cysteamine gold nanoparticles; The anti-PSA antibody is coated onto the cysteamine gold nanoparticles to prepare a PSA antibody-gold nanoparticle composite recognition probe.

9. The method for preparing a prostate specific antigen assay kit according to claim 8, characterized in that: The cysteamine gold nanoparticles are prepared by the following steps: Weigh mercaptoethylamine, chloroauric acid and sodium borohydride in parts by weight to prepare mercaptoethylamine solution, chloroauric acid solution and sodium borohydride solution respectively; Mix the mercaptoethylamine solution and the chloroauric acid solution to obtain a mixed solution; adding sodium borohydride solution into the mixed solution to carry out a reduction reaction, thereby obtaining cysteamine gold nanoparticles; The step of coating the anti-PSA antibody onto the cysteamine gold nanoparticles to prepare the PSA antibody-gold nanoparticle composite recognition probe comprises: adding the first blocking agent to the anti-PSA antibody to block the amino site to obtain a first blocking antibody; adding EDC and NHS simultaneously to the first blocking antibody to activate the carboxyl site, thereby obtaining an activated anti-PSA antibody; The activated anti-PSA antibody and the cysteamine gold nanoparticles are subjected to a coupling reaction, and a second blocking agent is added to obtain a PSA antibody-gold nanoparticle composite solution; Trifluoroacetic acid was added to the PSA antibody-gold nanoparticle composite solution, and the PSA antibody-gold nanoparticle composite recognition probe precipitate was obtained after centrifugation. The supernatant was removed and the solution was re-dissolved with Tris buffer.

Citation Information

Patent Citations

  • Kit for detecting PSA (prostate specific antigen) and application thereof

    CN106932570A

  • Preparation methods of latex microsphere and antibody compound, product and application thereof

    CN110441514A

  • Prostate-specific antigen detection reagent and kit

    CN110632040A

  • Free prostate specific antigen detection kit and preparation method thereof

    CN110988348A

  • Sensitive total prostate specific antigen detection kit

    CN113866412A